Research Objectives
This study aims to investigate the mechanisms and potential treatments for ARHL through a multifaceted approach. By studying hyperglycemia-induced maternal mice and their offspring at various ages, we hope to understand how glucotoxicity affects the inner ear and auditory system, ultimately providing scientific evidence for clinical approaches to prevent and treat hyperglycemia-induced hearing loss. The study will also explore the link between gut microbiota, ARHL, and AD. By leveraging large-scale data analysis and validating findings in AD model mice, we aim to elucidate the molecular mechanisms of ARHL, particularly its impact on the central nervous system. This research will further assess the therapeutic potential of targeting gut microbiota to address both ARHL and AD.
Role of the UK Biobank
The UK Biobank (UKB) will play a pivotal role in this research, providing access to a vast array of genetic, phenotypic, and lifestyle data. This dataset will allow us to:
· Identify genetic variants and biomarkers related to ARHL, especially in patients with a history of diabetes or cognitive decline.
·Validate the molecular links between ARHL and AD identified in animal models through comparison with human data.
·Analyze epidemiological data to explore trends in ARHL and AD, improving disease modeling and refining potential therapeutic targets.
·Investigate the role of gut microbiota in ARHL and AD by leveraging UKB’s comprehensive microbiome dataset.
